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pathtracer: High-sensitivity 
detection of differential pathway 
activity in tumours
Ståle nygård1,2,9, Ole Christian Lingjærde1,3,4,9, Carlos Caldas  5, Eivind Hovig  1,6,  
Anne-Lise Børresen-Dale3, Åslaug Helland3,7,8 & Vilde D. Haakensen  3,7*
Gene expression profiling of tumours is an important source of information for cancer patient 
stratification. Detecting subtle alterations of gene expression remains a challenge, however. Here, we 
propose a novel tool for high-sensitivity detection of differential pathway activity in tumours. For a 
pathway defined by a collection of genes, the samples are projected onto a low-dimensional manifold in 
the subspace spanned by those genes. For each sample, a score is next found by calculating the distance 
between each projected sample and the projection of a subgroup of reference samples. Depending 
on the aim of the analysis and the available data, the reference samples may represent e.g. normal 
tissue or tumour samples with a particular genotype or phenotype. The proposed tool, PathTracer, is 
demonstrated on gene expression data from 1952 invasive breast cancer samples, 10 DCIS, 9 benign 
samples and 144 tumour adjacent normal breast tissue samples. PathTracer scores are shown to predict 
survival, clinical subtypes, cellular proliferation and genomic instability. Furthermore, predictions are 
shown to outperform those obtained with other comparable methods.
Cancer initiation and progression involves deregulation of multiple signalling and metabolic pathways1. However, 
within the set of tumours being subject to deregulation of a particular pathway, the specific genomic and tran-
scriptomic alterations can vary substantially. As a consequence, it can be challenging to link cancer progression to 
aberrations of a particular gene. Estimating the activity of pathways rather than single genes seeks to alleviate this 
problem by accumulating evidence of deregulation across all genes in a pathway, increasing the sensitivity compared 
to single-gene analyses. The identification of altered pathways may also facilitate development of personalised cancer 
treatments by identifying the main driving mechanisms in each tumour2,3. Notably, in recent years, cancer combi-
nation therapies have emerged that target specific pathways in parallel or multiple targets in the same pathway4,5. 
Carcinogenic alterations may occur at different molecular levels affecting the same genes and pathways. Analysis at 
the pathway level may identify pathways that are affected by alterations at different levels and in different genes in the 
same pathways, eg: DNA mutations and aberrations in some genes, silencing by methylation or miRNA-regulation 
of others. Gene sets or pathways have been analysed in various ways6. Gene set enrichment and gene ontology anal-
yses identify genes that are significantly over-represented (enriched) in a gene list. The list is defined by an arbitrary 
threshold that may exclude significant genes. Construction of de novo networks of mutated/altered genes and their 
neighbours discards previous knowledge about biological function, but may identify known genetic associations. 
Finally, network-based modelling uses prior knowledge about networks/pathways to identify alterations in cancer.
PARADIGM7 was one of the first methods trying to meet the challenge of personalised pathway analysis, by 
describing the deregulation in a particular individual, as opposed to characterising a pathway’s activity for an 
entire sample set. Another such pathway-based method was Pathifier2. Pathifier calculates for every pathway 
a so-called Pathway Deregulation Score (PDS) representing the extent to which the pathway is deregulated in 
every individual sample. Pathifier utilises a non-linear analogy to principal components called principal curve8. 
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Specifically, each tumour sample is projected onto the principal curve before calculating the distance to the cen-
troid of the normal samples. A potential challenge using principal curves to represent the underlying data is that 
not all data can be represented by a single non-linear principal component. In that case, the behaviour of the 
principal curve approach will be unpredictable. Samples with high deregulation of a particular pathway will be 
located far from the normal samples in the multidimensional expression space, and we expect them to be located 
at the extreme end of the curve. However, if the principal curve does not represent the data well, this may not be 
the case (see file loops.html at github.com/staaln/pathtracer for several real-world examples). In such cases, the 
most deregulated samples may be located far from the extreme ends of the curve and then the distance from the 
tumour sample along the curve to the normal samples does not reflect the degree of deregulation. We propose to 
avoid this problem by using instead the Euclidean distance between two points on the principal curve, one repre-
senting the centroid of the normal samples and the other the projection of the tumour sample.
Methods
The data input for the PathTracer method is a genome-wide gene expression profile (e.g from RNA-sequencing or 
microarray data) for a collection of samples of interest (e.g tumour samples), as well as for a collection of reference 
samples (e.g normal samples). First, expression values are gene-centered by subtraction of the mean and gene-scaled 
by division with the standard deviation. This standardisation is performed to ensure that all genes are on the same 
scale, otherwise the highly expressed genes will dominate in the principal components that will be constructed in the 
subsequent analysis. We assume the data to be normalised between samples prior to the analysis.
The method considers one pathway at a time, extracting gene expression data in all n samples for the genes in the 
pathway. For a pathway consisting of p genes, we thus obtain an n × p matrix E of gene expression values, and for the i 
th row (sample) we have a label Li indicating whether the row represents a sample of interest or a reference sample. We 
here assume, without loss of generality, that the samples of interest are tumour samples and reference samples are from 
normal tissue (i.e Li = “tumour” or Li = “normal”, i = 1, …, n). We will only consider pathways above a given size, as 
pathways with very few genes are likely to give unstable results. We first derive a low-dimensional feature vector zi ∈ Rm 
for the i th sample, where m ≪ p. The components of the vector zi are the first m scores from a principal component 
analysis (PCA) derived from the gene expression matrix E. The number of components m may be fixed in advance or 
estimated from the data. We now have a reduced data matrix E  of dimension n × m where rows represent samples and 
columns represent features. The next step reduces the dimension even further from the m- dimensional feature vectors 
zi to one-dimensional scores. To do this, a principal curve8 is fitted to the sample feature vectors zi. The first component 
in classical PCA is the line minimising the sum of squared distances from the data points to their orthogonal projec-
tions onto the line. A principal curve is analogous, except that the line is replaced by a smooth curve. Fitting a principal 
curve involves a trade-off between smoothness (degree of deviation from a straight line) and goodness-of-fit to the data. 
This trade-off is governed by a model parameter λ > 0 which is determined by cross-validation.
An overview of the method is illustrated in Fig. (1a). From the principal curve, we obtain a score for each sample as 
follows. Each m-dimensional feature vector zi has an orthogonal projection P(zi) = pi onto the principal curve 
(see Fig. 1b). If multiple projections exist, the nearest is selected. Let O denote an arbitrary point on the principal 
curve, and for each sample let di be the signed distance along the curve from the projection pi to O. O can for 
example be taken as the starting point s of the principal curve. (Note that the di's then correspond to the path-
way deregulation scores, PDS, in the Pathifier algorithm2). Let k be the index of the normal sample for which 
dk = median(di) where the median is calculated across all normal samples (if the number of normal samples is 
even, choose k to minimize the distance between the left and right hand side). Let cN = P(zk) = pk be the projection 
onto the principal curve of this normal sample. For the i th sample, define the score ei = ||pi − cN||, i.e the Euclidean 
Algorithm 1. The PathTracer algorithm.
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distance between pi and cN (see Fig. 1c). Then scale the score so it becomes between 0 and 1 by dividing it 
by the maximum score value emax = maxk∈1, …, nek. The PathTracer algorithm is summarised in the table below.
The number of principal components m in 2(b) must also be chosen. The optimal m will handle the 
bias-variance trade-off by including enough PCs to avoid underfitting, but at the same time avoiding overfitting 
by including enough PCs. We evaluated the performance in terms of survival prediction on training and test sets, 
and found that m = 4 gave the best results on the test set, but that results were quite stable in the range of m ∈ {3, 
…, 10}. See Supplementary Fig. 1. The minimum number of genes in a pathway pmin must also be chosen. In our 
application we have used pmin = 10, i.e about twice the number of principal components.
Material. The breast cancer dataset used for the analyses has previously published as the Metabric dataset 
and the samples were collected in five different hospitals in the UK and Canada as previously described9. The 
METABRIC study collected samples from existing biobanks and the study was approved by the ethics committees 
in Cambridge and Vancouver ensuring that the methods were carried out in accordance with relevant guidelines 
and regulations. The expression data are available at the European Genome-phenome Archive (http://ebi.ac.uk/
ega/) at the European Bioinformatics Institute (accession number EGAS00000000083). The Illumina HT-12 v3 
platform was used for whole genome expression profiling9. This study has only used data available in the original 
publication. The cohort consists of a total of 2115 samples including 1952 invasive breast cancer samples, 10 
DCIS, 9 benign samples and 144 tumour adjacent normal breast tissue samples.
Results
Breast cancer: normal vs tumour. The PathTracer algorithm was applied to whole genome gene expres-
sion data from the Metabric breast cancer cohort including 1952 breast cancer samples 10 DCIS, 9 benign sam-
ples and 144 adjacent normal breast tissue samples9. Pathways were downloaded from the Reactome database, 
extracting all Homo sapiens pathways (n = 1288) using the reactome.db R/Bioconductor package10,11.
The file loops.html (github.com/staaln/pathtracer/) shows a selected set of pathways where the original points 
are plotted together with the principal curve in rotatable 3d figures. For many of the pathways we see that the 
principal curve is quite far from many of the original points. We also see, as for example for the Defensin pathway, 
that the principal curve “back-flips”, and almost forms a loop formation. We note that even though the normal 
samples are quite close in terms of Euclidean distance, they are very from each other in terms of distance along 
the principal curve, and would thus get a very high PDS value. We also note that for this pathway the correlation 
between the PDS and the PTS is very low (Pearson correlation = −0.08). A low correlation between PDS and 
PTS will in general be indicative of such loop-like principal curve formation. We therefore calculated the Pearson 
correlation between PDS and PTS for all pathways (See Supplementary Fig. 2), and found that 72 pathways had 
correlation less than 0.5 and 459 less than 0.75, which indicates that quite a few pathways have a back-flipping 
principal curve, although for the majority of pathways this will not be a substantial problem.
The samples were clustered to illustrate potential use of the PathTracer method. For illustrational purposes, we 
reduced the number of pathways substantially to include only pathways with PathTracer Scores (PTS) separating 
Figure 1. (a) Schematic overview of the PathTracer method. (b) Principal curve based on first two principal 
components. (c) Samples are projected onto the principal curve. Euclidean distance between the sample point pj 
and the reference point cN, i.e the length of the dotted line, defines the deregulation score for sample j.
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significantly between tumour and normal samples. In order to identify these pathways, we calculated the Area 
Under the Receiver Operating Characteristic (ROC) Curve (AUC). In a ROC curve, true positive rate or sensitiv-
ity (y-axis) is plotted against false positive rate or 1-specificity (x-axis) for the whole range of specificities. Here, 
Figure 2. (a) Heatmap of pathways with AUC > 0.98 in separating normal (n = 144) and tumour samples 
(n = 1971). Blue and red colours indicate low and high PathTracer score, respectively. (b) Heatmap of pathways 
with AUC > 0.7 in separating tumour samples with (n = 387) and without (n = 1008) TP53-mutation. Blue 
and red colours indicate low and high PathTracer score, respectively. (c) Kaplan Meier curves of breast cancer 
specific surivival for the Metabric dataset for the six clusters identified in (a). (d) Kaplan Meier curves of breast 
cancer specific survival for the Metabric dataset with tumour samples only, for the five clusters identified in (b).
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tumour and normal samples were regarded as positives and negatives, respectively, and true positive rate and false 
positive rate for a given PTS threshold value was defined as the number of tumour samples and normal samples, 
respectively, with PTS over the threshold value. Based on the PTS of the pathways with AUC ≥ 0.98 (n = 322), we 
identified a total of six sample clusters highly associated with tissue type (P = 0.000), ER-status (P = 2.2E − 100), 
the expression based PAM50 breast cancer subtypes (P = 3.4E − 288), and the previously published Integrated 
Clusters subtypes12 (P = 9.6E − 272)(chi squared tests) (Fig. 2a). The six clusters were also associated with TP53 
mutation status, lymph node status, Risk of recurrence (ROR) group13, genomic instability index (GII), prolif-
eration score and HER2-status (Fig. 2a). Breast cancer specific survival (BCSS) is significantly different between 
clusters (BCSS: P < 2.0E − 12; log-rank test) (Fig. 2c).
The heatmap in Fig. 2a reveals that most pathways are separating normal and tumour samples to a high 
degree. The first sample cluster consists mainly of normal samples (n = 140), but also contains 4 benign sam-
ples and 14 malignant tumour samples. These tumour samples are classified as normal-like (14/14) by PAM50 
and as IC4 (14/14) by IntClust, of which 12 are IC4ER+ and 2 IC4ER−. The samples classified as poor risk 
according to ‘Risk of Recurrence’ (ROR) cluster with the poor prognosis subtypes basal-like, HER2-enriched 
and IC5 in cluster 5 and 6 (orange and red). The orange samples (cluster 5) consist mainly of samples classified 
as basal-like (PAM50 red) and IC5 (IntClust purple), both characterised by poor prognosis (ref Curtis and Sorlie 
PNAS 2001). This sample cluster sees higher PTS than the other sample clusters in pathways involved in cell cycle 
(APC/C-mediated degradation and mitosis), transcription (polymerase), apoptosis and DNA-repair (transle-
sion) (Fig. 2a). The green and blue sample clusters 2 and 3 are characterised by low risk of relapse, low prolif-
eration, genomic aberration and TP53 mutation. For sample cluster 2 (green) most samples belong to IC4ER+ 
and IC3 and normal-like or luminal A subtypes, while sample cluster 3 (blue) contains mainly samples of IC3 
and luminal A subtypes. Both the gene-expression based PAM50 subtypes and the IntClust (based both on gene 
expression and genomic data) are highly associated with the clustering observed based on pathway deregula-
tion (p = 3.4 × 10–288 and p = 9.6 × 10–272, Fig. 2a). Figure (2c) shows Kaplan-Meier plots with p-value from 
log-rank test for survival-differences between the clusters in Fig. (2a)).
PathTracer deregulation scores were correlated with proliferation score, genome instability index (GII) 
(Fig. 3a) and overall survival (Table 1). To determine GII, we first applied the Allele Specific Copy number 
Aberrations in Tumours (ASCAT) algorithm14 to Affymetrix SNP6 data from all the samples to estimate the 
exact copy number along the genome. We next defined GII as the proportion of the genome with estimated copy 
number deviating from the average copy number in either direction by at least 0.5. The proliferation score was 
calculated as the mean expression of the 11 proliferation genes CCNB1, UBE2C, BIRC5, KNTC2, CDC20, PTTG1, 
RRM2, MKI67, TYMS, CEP55, and CDCA1, as previously described13. Gene centering was performed before 
calculation of the proliferation score. The Pearson correlation between PathTracer scores (PTS) and Genome 
Instability Index (GII) across pathways (median: 0.29, IQR: 0.20–0.37) was significantly higher than the correla-
tion between the Pathifier deregulation scores PDS (PDS) and GII (median:0.13, IQR:0.04–0.25) (P < 2.2·10−16; 
Fig. 3a). The Pearson correlation between PTS and the proliferation score (median: 0.31, IQR: 0.20–0.45) was also 
significantly higher than the correlation between PDS and proliferation score (median: 0.13, IQR: −0.02–0.29) 
(P < 2.2·10−16; Fig. 3a. We next performed Cox regression on breast cancer specific survival calculated from time 
of diagnosis, using either PTS or PDS as the covariate. The proportion of pathways having a significant association 
to survival (P < 0.05) is higher for PTS than for PDS for a range of different significance thresholds (see Table 1). 
The deregulation scores were also correlated to PAM50 subtypes13 using two well-known pathways, namely Cell 
Cycle pathway and DNA Repair pathway. Figure 3b,d show the samples projected onto the principal curves and 
coloured according to PAM50 subtypes. After the normal samples, which are located mostly at the start of the 
curves, we find predominantly normal-like samples followed by LumA, LumB, Her2, and finally, Basal-like sam-
ples. This is an ordering which fits well with severity of disease. The boxplots in Fig. 3c,e include also the PDS 
values for comparison. We see that the PTS values in general are higher than the PDS values, but more notably 
for the LumA, LumB, Basal-like and Her2 subtypes, implying that the PTS values are more highly correlated with 
cancer severity (according to PAM5 subtype) than the PDSs.
Breast cancer: TP53 mutated vs. TP53 wild-type. To illustrate an alternative use of the method (with-
out reference to normal tissue samples), we have identified PTSs comparing TP53 mutated and wild-type samples 
for tumours in the Metabric dataset using wild-type samples as reference group. Figure 2b illustrates clustering 
of the samples based on pathways with an AUC > 0.7 (n = 364). The red sample cluster 1 is characterised by high 
PTS, ROR-risk, GII and proliferation, a large proportion of TP53-mutation and an enrichment in basal-like and 
IC10 subtypes. Kaplan-Meier plots confirm the poor prognosis (Fig. 2d). The samples in cluster 1 are charac-
terised by high PTS in pathways related to cell cycle, gene expression and metabolism of proteins. The path-
ways constituting the lower 8 lines of the heatmap show a high PTS in both poor prognosis sample clusters 
(red sample cluster 1 and the pink sample cluster 4) and are all involved in regulation of cell cycle, specifically 
p53-independent DNA damage response, APC/C-mediated degradation and CDK-mediated removal of CDC6). 
Two sample clusters are characterised by a majority of TP53 wild-type ER positive samples; cluster 2 (yellow) 
and cluster 5 (blue). Both are dominated by luminal A and IC3 samples and have a good prognosis (Fig. 2d). The 
yellow sample cluster 2 has a higher representation of normal-like and IC4+ samples and the blue sample cluster 
5 has a higher representation of luminal B, IC7 and IC8 samples. The pathways in the lower pink pathway cluster 
5 have a high PTS in the poor prognosis red sample cluster 1 and includes mainly pathways involved in cell cycle. 
These pathways also have a high PTS in those samples belonging to the pink sample cluster 4 that have a high risk 
of relapse according to ROR.
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Figure 3. (a) Box plots of the Pearson correlation between deregulation scores (PTS/PDS) and Genome 
Instability Index (GII) (left) and proliferation index (right) using the Metabric dataset with n = 1971 tumour 
samples and n = 144 normal samples and 1288 human Reactome pathways. (b) Projection of samples onto the 
principal curve for the Cell cycle pathway using the Metabric dataset. The samples are coloured according to 
PAM50 subtype. The median PahtTracer score for each subtype is given by the length of the dotted lines. (c) 
Comparison of Pathifier (PDS) and PahtTracer (PTS) deregulation scores for each of the PAM50 subtypes using 
the Metabric dataset. (d) Projection of samples onto the principal curve for the DNA repair pathway using the 
Metabric dataset. The samples are coloured according to PAM50 subtype. The median PathTracer score for 
each subtype is given by the length of the dotted lines. (e) Comparison of Pathifier (PDS) and PahtTracer (PTS) 
deregulation scores for each of the PAM50 subtypes using the Metabric dataset.
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Discussion
Analysis of pathway deregulation in cancer captures alterations at different molecular levels as well as in different 
genes in the pathway and may give an overview of biological alterations in carcinogenesis and characteristics par-
ticular to a specific tumour. Identifying pathway deregulation allows identification of combined alterations that 
affect the cancer biology more than identifying single mutations. This is important for a broader understanding 
of the biology, but also for the development of new treatment strategies and for understanding treatment failure.
PathTracer identifies deregulation of a user-defined list of input pathways in cancer samples compared with a 
specified set of normal (reference) samples. Use of the method may be exploratory by including a wide range of 
pathways to identify which are most deregulated. The method may also be used for studying the behaviour of a 
specific set of pathways related to one or a few biological functions.
The motivation for developing PathTracer was the worry that previous methods would estimate an unjustified 
high deregulation score to certain pathways. The presented method is similar to the Pathifier method2, in that 
it utilizes principal curves to obtain deregulation scores, but differ in many ways, affecting both robustness of 
results, computational time, and output visualisation. Most importantly, we have implemented a novel distance 
measure method to address the problem of pathways where the principal curve goes in a loop. Pathifier will in 
such situations estimate the deregulation score along the curve and assign a high deregulation score to a sam-
ple located at the tail of the curve but close to the reference samples. The biological meaning of such a score is 
questionable. By using the Euclidean distance from the projection of the sample onto the principal curve to the 
reference point cN, the samples will get a deregulation score that reflects the distance from the sample to the refer-
ence samples in a multidimensional space and which is more likely to reflect the underlying biology. In addition 
to the problem with principal curves going in loops, one may get unreliable results if the curves are very ragged 
(non-smooth), because such curves will generate long distances along the curves (and very high deregulation 
score), even though the Euclidean distances to the reference point may not be long. To further improve robust-
ness, PathTracer has an optional pre-filtering step where pathways with fewer than k genes are omitted from the 
analysis (in the reported results, we use k = 10). The rationale behind this pre-filtering is that pathways consisting 
of very few genes are less likely to benefit from the dimension reduction step in PathTracer. There is a trade-off 
involved here, however, as one may risk missing key pathways by such filtering. We would therefore recommend 
that use of pre-filtering is used with caution if one suspects that important pathways may thus be discarded. 
Further, as pathway analyses tend to be extremely time consuming, substantial changes to decrease computational 
time has been implemented. The most time-consuming part in the Pathifier method is a cross-validation proce-
dure to find the optimal number of principal components (PCs). By instead locking the number of PCs, we reduce 
the computational time about 10-fold. In addition, we have added the possibility of performing parallelization, 
which enables the user to run the analysis on several cores simultaneously, drastically reducing the calculation 
time. Several features enabling data presentation have been incorporated in the PathTracer method, including 
generation of a heatmap with clustering of samples and deregulation scores including significance testing between 
the input categories for each pathway. A principal curve plot for each pathway may help interpret the results and 
help the researcher understand the biology underlying the figures produced by the algorithm.
The PathTracer method was applied to a set of breast cancer samples to illustrate its use. Survival and the bio-
logical features genome instability index and proliferation score show increased correlation with PTS (PathTracer) 
compared with PDS (Pathifier). Clustering based on PTS identified clusters with varying degree of pathway 
deregulation and a high correlation with clinical and biological features.
Data availability
We have developed an R-package called PathTracer available on GitHub (github.com/staaln/pathtracer).
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Threshold PDS PTS Ratio
0.05 0.537 0.680 1.186
0.04 0.514 0.650 1.265
0.03 0.481 0.615 1.279
0.02 0.443 0.559 1.262
0.01 0.375 0.469 1.251
0.005 0.313 0.386 1.233
0.001 0.198 0.237 1.196
0.0001 0.078 0.119 1.525
0.00001 0.013 0.051 3.920
Table 1. Proportion of significant pathways in Cox regression of overall survival. The first column in the table is 
the threshold used to determine if a Cox-regression P-value is significant, the second column is the proportion 
of pathways significant with Pathway Deregulation Score (PDS) as covariate, the third column is the proportion 
of pathways significant with PathTracer Score (PTS) as covariate, and the fourth column is the ratio between the 
third and the second column. In the figure the threshold values (first column) are plotted against the proportion 
of significant pathways PDS (black colour) and PTS (red colour).
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